{"id":"NCT00666835","sponsor":"Sandoz","briefTitle":"Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients","officialTitle":"Randomized, Double-blind, Multicenter, Parallel-group, Equivalence Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-04","primaryCompletion":"2006-01","completion":"2006-01","firstPosted":"2008-04-25","resultsPosted":"2017-08-02","lastUpdate":"2023-07-03"},"enrollment":478,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"HX575 epoetin alfa Hexal AG","otherNames":["Binocrit, Abseamed"]},{"type":"DRUG","name":"ERYPO®, Janssen-Cilag","otherNames":["EPREX®","Solution for i.v. injection"]}],"arms":[{"label":"HX575 epoetin alfa Hexal AG","type":"EXPERIMENTAL"},{"label":"ERYPO®, Janssen-Cilag","type":"ACTIVE_COMPARATOR"}],"summary":"This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia and treated previously with a stable dose of ERYPO® intravenously.","primaryOutcome":{"measure":"To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.","timeFrame":"28 weeks","effectByArm":[{"arm":"HX575 Epoetin Alfa Hexal AG","deltaMin":0.147,"sd":0.092},{"arm":"ERYPO®, Janssen-Cilag","deltaMin":0.063,"sd":0.117}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":28},"locations":{"siteCount":54,"countries":["Austria","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":112,"n":314},"commonTop":["Muscle spasms","Nasopharyngitis","Diarrhoea","Haemodialysis-induced symptom","Hypotension"]}}